Home › Astrocytoma › Illinois
Astrocytoma clinical trials in Illinois
9 studies for Astrocytoma are looking for participants at sites in Illinois.
Cities in Illinois
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05765812Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 18 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.